Enhanced solubility and functionality of valrubicin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticles

References

• CaruthersSDWicklineSALanzaGMNanotechnological applications in medicineCurr Opin Biotechnol2007181263017254762
   PubMed Web of Science ®Google Scholar
• JainKKApplications of nanobiotechnology in clinical diagnosticsClin Chem200753112002200917890442
   PubMed Web of Science ®Google Scholar
• DavisMEChenZShinDMNanoparticle therapeutics: an emerging treatment modality for cancerNat Rev Drug Discov20087977178218758474
   PubMed Web of Science ®Google Scholar
• GuoDDXuCXQuanSJSynergistic anti-tumor activity of paclitaxel-incorporated conjugated linoleic acid-coupled poloxamer thermosensitive hydrogel in vitro and in vivoBiomaterials200930274777478519524293
   PubMed Web of Science ®Google Scholar
• FreitasCMüllerRHCorrelation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phaseEur J Pharm Biopharm199947212513210234536
   PubMed Web of Science ®Google Scholar
• UnerMYenerGImportance of solid lipid nanoparticles (SLN) in various administration routes and future perspectivesInt J Nanomedicine20072328930018019829
   PubMed Web of Science ®Google Scholar
• YangSCLuLFCaiYZhuJBLiangBWYangCZBody distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brainJ Control Release199959329930710332062
   PubMed Web of Science ®Google Scholar
• HuLDTangXCuiFDSolid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugsJ Pharm Pharmacol200456121527153515563759
   PubMed Web of Science ®Google Scholar
• MüllerRHRadtkeMWissingSANanostructured lipid matrices for improved microencapsulation of drugsInt J Pharm20022421–212112812176234
   PubMed Web of Science ®Google Scholar
• LackoAGNairMParanjapeSJohnsoSMcConathyWJHigh density lipoprotein complexes as delivery vehicles for anticancer drugsAnticancer Res20022242045204912174882
   PubMed Web of Science ®Google Scholar
• LackoAGNairMParanjapeSMooberryLMcConathyWJTrojan horse meets magic bullet to spawn a novel, highly effective drug delivery modelChemotherapy200652417117316691026
   PubMed Web of Science ®Google Scholar
• LackoAGNairMProkaiLMcConathyWJProspects and challenges of the development of lipoprotein-based formulations for anti-cancer drugsExpert Opin Drug Delivery200746665675
   PubMed Web of Science ®Google Scholar
• McConathyWJNairMParanjapeSMooberryLLackoAGEvaluation of synthetic/reconstituted high density lipoproteins (rHDL) as delivery vehicles for paclitaxelAnticancer Drugs200819218318818176115
   PubMed Web of Science ®Google Scholar
• ShahzadMMMangalaLHanHTargeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticlesNeoplasia201113430931921472135
   PubMed Web of Science ®Google Scholar
• MooberryLKNairMParanjapeSMcConathyWJLackoAGReceptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrierJ Drug Target2010181535819637935
   PubMed Web of Science ®Google Scholar
• McConathyWJParanjapeSMooberryLButtreddySNairMLackoAGValidation of the reconstituted high-density lipoprotein (rHDL) drug delivery platform using dilauryl fluorescein (DLF)Drug Deliv and Transl Res201112113120
   Web of Science ®Google Scholar
• VecchiACairoMMantovaniASironiMSpreaficoFComparative antineoplastic activity of Adriamycin and N- trifluoroacetyladriamycin-14-valerateCancer Treat Rep1978621111117626989
   PubMedGoogle Scholar
• IsraelMModestEJFreiEIIIN-trifluoroacetyl adriamycin-14-valerate, an analog with greater experimental antitumor activity and less toxicity than adriamycinCancer Res1975355136513681054622
   PubMed Web of Science ®Google Scholar
• KrishanAIsraelMModestEJDifferences in cellular uptake and cytofluorescence of Adriamycin and N-trifluoroacetyladriamycin-14-valerateCancer Res1976366210821091268863
   PubMed Web of Science ®Google Scholar
• WilkinsonPMIsraelMPeggWJFreiE3rdComparative hepatobiliary metabolism and excretion of adriamycin (ADR) and N-trifluoroacetyladriamycin-14-valerate (AD82) in the ratCancer Res1978382365370620407
   PubMed Web of Science ®Google Scholar
• WitjesJACurrent recommendations for the management of bladder cancer drug therapyDrugs19975334044149074842
   PubMed Web of Science ®Google Scholar
• OnrustSVLambHMValrubicinDrugs Aging1999151697510459733
   PubMed Web of Science ®Google Scholar
• AndersenSMRosadaCDagnaes-HansenFTopical application of valrubicin has a beneficial effect on developing skin tumorsCarcinogenesis20103181483149020554745
   PubMed Web of Science ®Google Scholar
• RosadaCStenderupKde DarkóEDagnaes-HansenFKampSDamTNValrubicin in a topical formulation treats psoriasis in a xenograft transplantation modelJ Invest Dermatology20101302455463
   Web of Science ®Google Scholar
• RyanROForteTMOdaMNOptimized bacterial expression of human apolipoprotein A-IProtein Expr Purif20032719810312509990
   PubMed Web of Science ®Google Scholar
• LoneyWWKudchodkarBJWeissSClearfieldMBShoresJLackoAGEvaluation of gemfibrozil therapy: predictive response from lipoprotein sub fraction analysisAm J Ther199749–1030130910423623
   PubMedGoogle Scholar
• ForteTNorumKRGlomsetJANicholasAVPlasma lipoproteins in familial lecithin: cholesterol acetyltransferase deficiency: structure of low and high density lipoproteins as revealed by electron microscopyJ Clin Invest1971505114111485552411
   PubMed Web of Science ®Google Scholar
• KaighnMENarayanKSOhnukiYLechnerJFJonesLWEstablishment and characterization of a human prostatic carcinoma cell line (PC-3)Invest Urol19791711623447482
   PubMedGoogle Scholar
• FoghJFoghJMOrfeoTOne hundred and twenty-seven cultured human tumor cell lines producing tumors in nude miceJ Natl Cancer Inst1977591221226327080
   PubMed Web of Science ®Google Scholar
• MurakamiTWijagkanalanWHashidaMTsuchidaKIntracellular drug delivery by genetically engineered high-density lipoprotein nanoparticlesNanomedicine (Lond)20105686787920735223
   PubMed Web of Science ®Google Scholar
• Venier-JulienneMCMathieuDFilmonRPhan-Tan-LuuRBenoitJPDevelopment of 5-iodo-2′-deoxyuridine milling process to reduce initial burst release from PLGA microparticlesInt J Pharm1999178225726810205645
   PubMed Web of Science ®Google Scholar
• LeoECameroniRForniFDynamic dialysis for the drug release evaluation from doxorubicin-gelatin nanoparticle conjugatesInt J Pharm19991801233010089288
   PubMed Web of Science ®Google Scholar
• YangCRZhaoXLHuHYPreparation, Optimization and Characteristic of Huperzine A Loaded Nanostructured Lipid CarriersChem Pharm Bull (Tokyo)201058565666120460792
   PubMed Web of Science ®Google Scholar
• GreenbergRBahnsonRWoodDInitial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladderUrology19974934714759123721
   PubMed Web of Science ®Google Scholar
• ZhengJLeeHBin SattarMHuangYBianJCardioprotective effects of epigallocatechin-3-gallate against doxorubicin-induced cardiomyocyte injuryEur J Pharmacol20116521–3828821114975
   PubMed Web of Science ®Google Scholar
• IbsenSZahavyEWrasdiloWBernsMChanMEsenerSA novel doxorubicin prodrug with controllable photolysis activation for cancer chemotherapyPharm Res20102791848186020596761
   PubMed Web of Science ®Google Scholar